HIV AIDS

New study suggests HIV-1 infection is more virulent when transmitted through heterosexual penile-vaginal intercourse than through anal intercourse between men who have sex with men due to transmission bottlenecks.

The CDC update recommends that clinicians advise all sexually active patients about PrEP and includes a new section on prescribing injectable bimonthly cabotegravir.

Get 90% of all HIV-infected persons diagnosed, get 90% of them on ART, and get 90% of those on ART “undetectable.” Are we there yet?

The AAP updated its guidance to recommend routine HIV screening at least once in all adolescents aged ≥15 years and at-risk youth be rescreened annually.

Nearly 25% of patients with HIV who use antiretroviral therapy will reach 65 years of age or older by 2030, researchers projected in a new analysis.

IDWeek 2021: Despite declining mortality rates among patients with HIV in the past 2 decades, a new study finds significant disparities in gender and race.

Viral-load monitoring rates decreased and clinic visits declined overall despite an increase in use of telehealth.

Patients with HIV had a 14% higher risk of sudden cardiac death than those without HIV, according to a large analysis of US veterans.

Rodger MacArthur, MD, was in his HIV clinic last week and queried his COVID-19 vaccine-hesitant/resistant patients about their reasons. The refrain was familiar and discouraging.

Vaccines from both companies were significantly effective against COVID-19 and show promise against variants from the UK and South Africa.

Cabotegravir and rilpivirine, injectable formulation is administered once-weekly, reducing treatment days for adults with HIV from 365 to 12.

The FDA announced October 3 approval of Descovy®, making it the second drug to receive indication for HIV pre-exposure prophylaxis.

The underpinnings of the global HIV and STI epidemics are inextricable. A new report looks at combined solutions. We offer highlights.

Highlights: The first liquid solution of colchicine for prophylaxis of gout, the first generic version of Advair Diskus, and 8 more new and approved drugs.

A first-of-its-kind study found that among cirrhosis patients with and without HIV-coinfection, liver function improved >50% in each cohort.

What are the top 5 HIV/AIDS apps that both physicians and patients can use? Scroll through our new slideshow to find out. 

Further hope for prevention of transmission as the search for a cure continues.

Research supports liver and kidney transplantation in patients with HIV infection, but referral rates are low.

Test your knowledge of the latest National Comprehensive Cancer Network guidelines for cancer in patients with HIV infection.

The use of pre-exposure prophylaxis for HIV prevention among men who have sex with men has doubled each year since 2012.

Both oral and anal sex have been linked to an increased risk of STD and HIV transmission in heterosexuals, say CDC researchers.

Structural barriers may explain the HIV epidemic among women in the American South.

Findings from the largest study to evaluate sex differences in HIV-related cognitive dysfunction.

This study may help alleviate doubts about whether laypersons can perform the test and interpret the results correctly on their own.

Results of this study suggest a combined epidemic of sexual ill-health, drug use harms, and mental illness among HIV-positive MSM who engage in slamsex and chemsex.

The "new year" is now in full swing and new drugs are being approved each month; check out our slideshow to get up to date on 9 drugs approved in the first quarter for primary care. 

PrEP can decrease risk of HIV transmission. It can also contribute to risky sexual behavior and STIs.

The population of children who had prenatal exposure to HIV and to antiretroviral agents who do not become infected with HIV is growing. What effect do ARVs have on neurodevelopment in this group?

A 34-year-old man with a history of HIV says family members are exaggerating his symptoms but that the headache and double vision are bothersome. 

Clinical trials of second generation direct-acting antivirals in HCV show high cure rates. But do those rates reflect real life?